References
- https://www.ema.europa.eu/en/human-regulatory/research-development/compassionate-use. European Medicines Agency (EMA). https://www.EmaEuropaEu/En/Human-Regulatory/Research-Development/Compassionate-Use n.d.
- Pignatti F, Gravanis I, Herold R, Vamvakas S, Jonsson B, Marty MThe European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulationClin Cancer Res20111752205225 10.1158/1078-0432.CCR-11-0623 21844037
- Martinalbo J, Bowen D, Camarero J, Chapelin M, Démolis P, Foggi P, et al.Early market access of cancer drugs in the EUAnn Oncol20162796105 1:STN:280:DC%2BC28zjvVSlsw%3D%3D 10.1093/annonc/mdv506 26487583
- Kempf E, Zalcman G, Lebbe CNational early access programs and clinical trials: what opportunities for early access to therapeutic innovations for patients with malignant melanoma?Cancer202112721812183 10.1002/cncr.33495 33788953
- IQVIA. EFPIA Patients W.A.I.T. Indicator 2021 Survey - Updated July 2022. https://www.EfpiaEu/Media/676539/Efpia-Patient-Wait-Indicator_update-July-2022_finalPdf n.d.
- Eichler H-G, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al.Bridging the efficacy–effectiveness gap: a regulator’s perspective on addressing variability of drug responseNat Rev Drug Discov201110495506 1:CAS:528:DC%2BC3MXotlCmuro%3D 10.1038/nrd3501 21720406
- Iudicello A, Alberghini L, Benini G, Mosconi PExpanded Access Programme: Looking for a common definitionTrials2016 10.1186/s13063-015-1108-0 26758369 4711042
- Urbinati D, Toumi MPHP147 Early Access Programmes (EAPs): review of the European SystemValue in Health201215A315 10.1016/j.jval.2012.08.689
- Taylor GJ, Wainwright POpen label extension studies: research or marketing?BMJ20053317516572574 1:STN:280:DC%2BD2MvotVCrtw%3D%3D 10.1136/bmj.331.7516.572 16150772 1200598
- Richard Chin BL. Principles and Practice of Clinical Trail Medicine. 1° Edition. 2008.
- Early Access Programs in Europe: A Regulatory Tool with Pre‐marketing Impact‐the Pharma Letter. http://www.ThepharmaletterCom/Article/Early‐access‐Programs‐in‐europe‐a‐regulatory‐tool‐with‐pre‐marketing‐Impact. Accessed 30 Apr 2015; 2008.
- Apolone G, Ardizzoni A, Buzzetti G, Clerico MA, Conte P, de Braud F, De Lorenzo F, Ferrandina MG, Genazzani A, Gori S, Maio M, Patroncini M, Perrone F, Scambia G, Scroccaro GEarly access in oncology: why is it needed?Glob Region Health Technol Assess.2019 10.1177/2284240319857072
- The European Medicines Agency (EMA) EA to M. https://www.ema.europa.eu/en/documents/leaflet/early-access-medicines-development-support-regulatory-tools_en.pdf. Accessed 24 Nov 2022.
- Simon EIntegrating managed access programs: global considerationsAppl Clin Trials.201523226
- Patil SEarly access programs: benefits, challenges, and key considerations for successful implementationPerspect Clin Res201674 10.4103/2229-3485.173779 26955570 4763516
- Jommi C, Pantellini F, Stagi L, Verykiou M, Cavazza MThe economic impact of compassionate use of medicinesBMC Health Serv Res2021 10.1186/s12913-021-07255-w 34863155 8645125
- Jommi C, Armeni P, Costa F, Alberti C, Bandello F, Bordonaro R, Caprodossi A, Di Maio M, Gaudioso A, Giuliani G, Langella R, Marata AM, Patarnello F, Pinto C, Rasi G, Villa FProgrammi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) [Early access programs and managed entry agreements for medicines in Italy: results of a Focus Group (Early Access Programs and Managed Entry Agreement).]Recent Prog Med2021112749756